IASO Bio Announces NDA Acceptance for Equecabtagene Autoleucel (FUCASO)
January 29, 2025
IASO Biotherapeutics, a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, announced that the Singapore Health Sciences